Janux Therapeutics, Inc. (JANX): Cash & Equivalents
$52.33M
As of 2025-12-31
$27.77M
As of 2026-06-30
+0.6%
3-year compound annual growth
+46.3%
5-year compound annual growth
| Period ended | Cash & Equivalents | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $52.33M | -87.8% | 2026-02-26, Balance as of period end |
| 2024-12-31 | $430.61M | n/m | 2026-02-26, Balance as of period end |
| 2023-12-31 | $19.20M | -62.7% | 2025-02-27, Balance as of period end |
| 2022-12-31 | $51.43M | +44.5% | 2024-03-08, Balance as of period end |
| 2021-12-31 | $35.58M | +355.4% | 2023-03-10, Balance as of period end |
| 2020-12-31 | $7.81M | n/a | 2022-03-18, Balance as of period end |
Cash & Equivalents at similar companies
| Company | Year ended | Cash & Equivalents | Change YoY |
|---|---|---|---|
| Janux Therapeutics, Inc. (JANX) | 2025-12-31 | $52.33M | -87.8% |
| Zenas BioPharma, Inc. (ZBIO) | 2025-12-31 | $110.64M | -65.4% |
| Precigen, Inc. (PGEN) | 2025-12-31 | $30.23M | +2.4% |
| Prothena Corp Public Ltd Co (PRTA) | 2025-12-31 | $307.53M | -34.8% |
| Crescent Biopharma, Inc. (CBIO) | 2025-12-31 | $213.19M | +513.2% |
| BioAge Labs, Inc. (BIOA) | 2025-12-31 | $188.89M | -46.7% |
| Jaguar Health, Inc. (JAGX) | 2025-12-31 | $968.0K | -87.9% |
| Roivant Sciences Ltd. (ROIV) | 2026-03-31 | $1.42B | -47.7% |
| Prelude Therapeutics Inc (PRLD) | 2025-12-31 | $35.26M | +182.6% |
Compare JANX, ZBIO, PGEN, PRTA side by side · Screen every company in Pharmaceutical Preparations ↗